Net sales were 1,861,129 thousand yen (Year-over-Year +4.1%), operating income was 182,640 thousand yen (Year-over-Year increase), ordinary income was 191,076 thousand yen, and quarterly net income was 142,180 thousand yen. Reporting segments were reorganized into two segments: Pharmaceuticals and Chemicals. Full-year forecasts for the fiscal year ending May 2027 were revised downward with updates to cumulative 2Q and full-year forecasts. Dividends are expected to be a total of 26.00 yen for the fiscal year ending May 2027, including a 13.00 yen year-end dividend.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4885","jir_company_name":"Muromachi Chemicals Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4885-20261015-01.pdf","jir_short_summary":"Net sales were 1,861,129 thousand yen (Year-over-Year +4.1%), operating income was 182,640 thousand yen (Year-over-Year increase), ordinary income was 191,076 thousand yen, and quarterly net income was 142,180 thousand yen. Reporting segments were reorganized into two segments: Pharmaceuticals and Chemicals. Full-year forecasts for the fiscal year ending May 2027 were revised downward with updates to cumulative 2Q and full-year forecasts. Dividends are expected to be a total of 26.00 yen for the fiscal year ending May 2027, including a 13.00 yen year-end dividend.","jir_summary":"### Performance Overview\nFor the quarter, net sales amounted to 1,861,129 thousand yen, a 4.1% increase year-over-year, and operating income reached 182,640 thousand yen, representing a substantial increase in profitability. Ordinary income was 191,076 thousand yen, and quarterly net income was 142,180 thousand yen, both showing significant increases, reflecting improved profitability. The reporting segments were changed to two segments: Pharmaceuticals and Chemicals; both segments performed steadily. The financial position improved with total assets of 5,867,332 thousand yen, net assets of 2,677,905 thousand yen, and an improved equity ratio of 45.6%. The full-year earnings forecast for the fiscal year ending May 2027 has been revised, reflecting certain uncertainties.\n\n### Outlook and Capital Policy\nCumulative results for the second quarter and full-year forecasts have been revised from previous announcements. The company forecasts net sales of 7,100 hundred million yen, operating income of 550 hundred million yen, ordinary income of 500 hundred million yen, and net income of 350 hundred million yen for the period, while noting that factors such as raw material costs and foreign exchange movements could affect quarterly fluctuations. Regarding dividends, the company maintains a forecast of a full-year dividend of 26.00 yen, including a 13.00 yen year-end dividend for the fiscal year ending May 2027. The company is aiming to improve capital efficiency and stabilize its financial base accordingly.","jir_financial_highlights":"Net Sales: 1,861,129 thousand yen (Year-over-Year +4.1%)\nOperating Income: 182,640 thousand yen (Year-over-Year +144.8%)\nOrdinary Income: 191,076 thousand yen (Year-over-Year +161.9%)\nQuarterly Net Income: 142,180 thousand yen (Year-over-Year +147.5%)\nEquity Ratio: 45.6% (From 40.6% at the end of the previous fiscal year \u2192 45.6%)","jir_category":"","jir_hashtags":"#MuromachiChemicals, #Earnings, #BusinessStructure, #FinancialPosition","jir_key_figures":"Net Sales: 1,861,129 thousand yen (Year-over-Year +4.1%)\nOperating Income: 182,640 thousand yen (Year-over-Year +144.8%)\nOrdinary Income: 191,076 thousand yen (Year-over-Year +161.9%)\nQuarterly Net Income: 142,180 thousand yen (Year-over-Year +147.5%)\nEquity Ratio: 45.6%","jir_meta_title":"[Muromachi Chemicals] Financial Summary for Q1 FY Ending May 2027 | Net Sales 1,861 million yen, Profit Growth","jir_meta_description":"Muromachi Chemicals Q1 financial summary for the fiscal year ending May 2027. Net sales 1,861,129 thousand yen, operating income 182,640 thousand yen. Reporting segments reorganized into Pharmaceuticals and Chemicals. Full-year forecasts revised. Dividend policy anticipates a full-year dividend of 26.00 yen.","jir_og_title":"Muromachi Chemicals Q1 Results: Significant Increase in Sales and Profit, Segment Reorganization","jir_og_description":"Muromachi Chemicals' Q1 financial results for the fiscal year ending May 2027: net sales up 4.1% year-over-year and substantial operating income increase. Announced segment reorganization and revised full-year forecasts.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-06\\\",\\\"2026-09\\\",\\\"2026-12\\\",\\\"2027-03\\\",\\\"2027-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales (thousand yen)\\\",\\\"data\\\":[1861,1787,0,0,0],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{}}\"}]","ir_related_company":60599,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-131900","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n